Log In Sign up
The largest database of trusted experimental protocols

Pifithrin μ

Manufactured by Abcam
Visit Supplier
Sourced in United Kingdom

Pifithrin-μ is a small molecule inhibitor that selectively inhibits the transcriptional activity of p53 by disrupting the interaction between p53 and the heat shock protein HSP70.

Automatically generated - may contain errors

Lab products found in correlation

Mg132, by Merck Group (2 mentions) Thapsigargin, by Merck Group (2 mentions) Withaferin a, by Merck Group (2 mentions) Cyclohexamide, by Merck Group (2 mentions) Powerplex 16 system, by Promega (2 mentions) Mycoalert mycoplasma detection kit, by Lonza (2 mentions) Actinomycin d, by Cambridge Bioscience (2 mentions)

2 protocols using pifithrin μ

1

AML Cell Line Authentication and Inhibitor Use

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human AML cell lines were purchased from the ATCC (THP1) and DSMZ (OCI-AML3, U937, MV4;11 and SHI-1), authenticated by short tandem repeat profiling using the PowerPlex 16 system (Promega, Southampton, UK) and mycoplasma negative status confirmed using the MycoAlert Mycoplasma Detection Kit (Lonza, Verviers, Belgium). The following reagents and inhibitors were used, Withaferin A (Merck Life Science UK, Dorset, UK and Cayman Chemical, Ann Arbor, MI, United States); Cyclohexamide, Thapsigargin and MG132 (Merck Life Science UK); Actinomycin D (Cambridge Bioscience, Cambridge, UK); pifithrin-μ. (Abcam, Cambridge, UK).
Clesham K., Walf-Vorderwülbecke V., Gasparoli L., Virely C., Cantilena S., Tsakaneli A., Inglott S., Adams S., Samarasinghe S., Bartram J., Williams G., de Boer J, & Williams O. (2022). Identification of a c-MYB-directed therapeutic for acute myeloid leukemia. Leukemia, 36(6), 1541-1549.
+ Open protocol
+ Expand
2

AML Cell Line Authentication and Inhibitor Use

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human AML cell lines were purchased from the ATCC (THP1) and DSMZ (OCI-AML3, U937, MV4;11 and SHI-1), authenticated by short tandem repeat profiling using the PowerPlex 16 system (Promega, Southampton, UK) and mycoplasma negative status confirmed using the MycoAlert Mycoplasma Detection Kit (Lonza, Verviers, Belgium). The following reagents and inhibitors were used, Withaferin A (Merck Life Science UK, Dorset, UK and Cayman Chemical, Ann Arbor, MI, United States); Cyclohexamide, Thapsigargin and MG132 (Merck Life Science UK); Actinomycin D (Cambridge Bioscience, Cambridge, UK); pifithrin-μ. (Abcam, Cambridge, UK).
Clesham K., Walf-Vorderwülbecke V., Gasparoli L., Virely C., Cantilena S., Tsakaneli A., Inglott S., Adams S., Samarasinghe S., Bartram J., Williams G., de Boer J, & Williams O. (2022). Identification of a c-MYB-directed therapeutic for acute myeloid leukemia. Leukemia, 36(6), 1541-1549.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!